Search research articles
Contact Us
Filters
Showing results (41-50 of 65) with videos related to
Page
of 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2025
Phase 2 trial of ponatinib in patients with metastatic gastrointestinal stromal tumor following failure or intolerance of prior therapy with imatinib (POETIG trial)
Johanna Falkenhorst, Phillipp Ivanyi, Tom Schulz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 9, 2024
<sup>68</sup>Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
Helena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 16, 2023
<sup>68</sup>Ga-Labeled Fibroblast Activation Protein Inhibitor (<sup>68</sup>Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the <sup>68</sup>Ga-FAPI PET Observational Trial
Lukas Kessler, Nader Hirmas, Kim M Pabst, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 20, 2023
<sup>68</sup>Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study
David Kersting, Patrick Sandach, Miriam Sraieb, et al.
Journal for Immunotherapy of Cancer
|
March 25, 2021
Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
Angelika M Starzer, Anna S Berghoff, Rainer Hamacher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 19, 2023
A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome
Rainer Hamacher, Xiaofei Liu, Markus K Schuler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 19, 2026
<sup>90</sup>Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis
Helena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2022
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
Wolfgang P Fendler, Kim M Pabst, Lukas Kessler, et al.
EJNMMI Research
|
March 13, 2026
Comparison between [<sup>68</sup>Ga]Ga-FAPI-46 and [<sup>18</sup>F]FDG PET/CT uptake in luminal-like vs. HER2-positive breast cancer
Alina Toni Küper, Sofia Carrilho Vaz, Kim Magaly Pabst, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 23, 2024
Prognostic Implications of <sup>68</sup>Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors
Masao Watanabe, Wolfgang P Fendler, Hong Grafe, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 65) with videos related to
Sort By:
Page
of 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2025
Phase 2 trial of ponatinib in patients with metastatic gastrointestinal stromal tumor following failure or intolerance of prior therapy with imatinib (POETIG trial)
Johanna Falkenhorst, Phillipp Ivanyi, Tom Schulz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 9, 2024
<sup>68</sup>Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
Helena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 16, 2023
<sup>68</sup>Ga-Labeled Fibroblast Activation Protein Inhibitor (<sup>68</sup>Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the <sup>68</sup>Ga-FAPI PET Observational Trial
Lukas Kessler, Nader Hirmas, Kim M Pabst, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 20, 2023
<sup>68</sup>Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study
David Kersting, Patrick Sandach, Miriam Sraieb, et al.
Journal for Immunotherapy of Cancer
|
March 25, 2021
Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
Angelika M Starzer, Anna S Berghoff, Rainer Hamacher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 19, 2023
A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome
Rainer Hamacher, Xiaofei Liu, Markus K Schuler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 19, 2026
<sup>90</sup>Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis
Helena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2022
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
Wolfgang P Fendler, Kim M Pabst, Lukas Kessler, et al.
EJNMMI Research
|
March 13, 2026
Comparison between [<sup>68</sup>Ga]Ga-FAPI-46 and [<sup>18</sup>F]FDG PET/CT uptake in luminal-like vs. HER2-positive breast cancer
Alina Toni Küper, Sofia Carrilho Vaz, Kim Magaly Pabst, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 23, 2024
Prognostic Implications of <sup>68</sup>Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors
Masao Watanabe, Wolfgang P Fendler, Hong Grafe, et al.
Page
of 7